Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial.

Gomaa, Adel A; Mohamed, Hamdy S; Abd-Ellatief, Rasha B; Gomaa, Mohamed A; Hammam, Doaa S

Gomaa, Adel A; Mohamed, Hamdy S; Abd-Ellatief, Rasha B; Gomaa, Mohamed A; Hammam, Doaa S.

Afiliação

Gomaa AA; Department of Medical Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt. a.gomma@aun.edu.eg.
Mohamed HS; Department of Internal Medicine, Faculty of Medicine, Sohag University, Sohag, Egypt.
Abd-Ellatief RB; Department of Medical Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Gomaa MA; Department of Plastic Surgery, Faculty of Medicine, Assiut University, Assiut, Egypt.
Hammam DS; Department of Pharmacology & Toxicology, Faculty of Pharmacy, Assiut University, Assiut, Egypt.

Inflammopharmacology ; 30(2): 477-486, 2022 Apr.

Article em En | MEDLINE | ID: mdl-35233748

Assuntos

Tratamento Farmacológico da COVID-19; Ácido Glicirrízico; Método Duplo-Cego; Feminino; Ácido Glicirrízico/efeitos adversos; Humanos; Masculino; Pessoa de Meia-Idade; SARS-CoV-2; Resultado do Tratamento

Palavras-chave

Boswellic aids; COVID-19; Clinical status score; Glycyrrhizin; Mortality rate; Time to recovery

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácido Glicirrízico / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google